Farther Finance Advisors LLC Grows Stock Holdings in Abbott Laboratories $ABT

Key Points

• Farther Finance Advisors LLC raised its stake in Abbott Laboratories by 19.7%, totaling approximately $5.37 million after purchasing additional shares during the second quarter.
• Abbott Laboratories reported a quarterly earnings of $1.26 EPS, meeting analysts' expectations, with a revenue increase of 7.4% compared to the previous year.
• The company announced a quarterly dividend of $0.59 per share, with the ex-dividend date set for October 15th, contributing to an annualized dividend yield of 1.7%.

Farther Finance Advisors LLC raised its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 19.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,491 shares of the healthcare product maker's stock after acquiring an additional 6,486 shares during the period. Farther Finance Advisors LLC's holdings in Abbott Laboratories were worth $5,371,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Silver Oak Securities Incorporated raised its holdings in Abbott Laboratories by 4.1% in the 2nd quarter. Silver Oak Securities Incorporated now owns 7,253 shares of the healthcare product maker's stock valued at $986,000 after acquiring an additional 284 shares in the last quarter. UMB Bank n.a. raised its holdings in Abbott Laboratories by 1.6% in the 2nd quarter. UMB Bank n.a. now owns 312,757 shares of the healthcare product maker's stock valued at $42,538,000 after acquiring an additional 4,854 shares in the last quarter. WealthBridge Investment Counsel Inc. raised its holdings in Abbott Laboratories by 1.8% in the 2nd quarter. WealthBridge Investment Counsel Inc. now owns 65,793 shares of the healthcare product maker's stock valued at $8,949,000 after acquiring an additional 1,150 shares in the last quarter. Shelton Wealth Management LLC raised its holdings in Abbott Laboratories by 379.1% in the 2nd quarter. Shelton Wealth Management LLC now owns 9,544 shares of the healthcare product maker's stock valued at $1,298,000 after acquiring an additional 7,552 shares in the last quarter. Finally, AA Financial Advisors LLC raised its holdings in Abbott Laboratories by 6.8% in the 2nd quarter. AA Financial Advisors LLC now owns 6,173 shares of the healthcare product maker's stock valued at $840,000 after acquiring an additional 394 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ABT has been the topic of a number of research reports. Leerink Partnrs upgraded Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. William Blair raised Abbott Laboratories to a "strong-buy" rating in a research note on Thursday, July 17th. Raymond James Financial dropped their price target on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a research note on Friday, July 18th. Wells Fargo & Company dropped their price target on Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating on the stock in a research note on Friday, July 18th. Finally, Royal Bank Of Canada boosted their price target on Abbott Laboratories from $145.00 to $147.00 and gave the company an "outperform" rating in a research note on Tuesday, July 15th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $145.22.

Insider Transactions at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.46% of the company's stock.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock traded down $0.57 during trading hours on Tuesday, reaching $136.05. The company had a trading volume of 2,986,462 shares, compared to its average volume of 6,637,777. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23. The business has a fifty day simple moving average of $130.56 and a 200 day simple moving average of $131.11. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The firm has a market cap of $236.78 billion, a PE ratio of 17.07, a price-to-earnings-growth ratio of 2.58 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts' consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. During the same period last year, the company earned $1.14 earnings per share. The business's revenue for the quarter was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.7%. Abbott Laboratories's dividend payout ratio (DPR) is currently 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.